Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKDGet Free Report) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 85,300 shares, an increase of 5.7% from the November 30th total of 80,700 shares. Based on an average trading volume of 70,100 shares, the short-interest ratio is currently 1.2 days. Currently, 7.8% of the shares of the company are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright upped their price target on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, November 11th.

Get Our Latest Analysis on Cadrenal Therapeutics

Cadrenal Therapeutics Stock Up 7.0 %

CVKD stock opened at $15.50 on Friday. The stock’s fifty day moving average price is $14.74. The company has a market cap of $27.64 million, a PE ratio of -2.32 and a beta of 1.22. Cadrenal Therapeutics has a fifty-two week low of $5.40 and a fifty-two week high of $32.55.

Cadrenal Therapeutics Company Profile

(Get Free Report)

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.

See Also

Receive News & Ratings for Cadrenal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadrenal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.